Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 7/20 | 0.78 |
| ▸ | GRM5 | P41594 | 1/20 | 0.76 |
| ▸ | CISD2 | Q8N5K1 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160814 | 0.87 | GRM6 (1.00) | GRM6GRM5KDM4EALDH1A1GAA | |
| SCHEMBL6157860 | 0.87 | TP53 (0.75) | GRM6GRM5KDM4EPKMALDH1A1 | |
| SCHEMBL7207512 | 0.87 | GRM6 (0.71) | GRM6GRM5CISD2KDM4EPKM | |
| SCHEMBL10714368 | 0.87 | GRM6 (1.00) | GRM6GRM5CISD2KDM4EPKM | |
| SCHEMBL6161028 | 0.86 | GRM6 (0.70) | GRM6GRM5CISD2KDM4EPKM | |
| SCHEMBL14485713 | 0.80 | OPRD1 (0.56) | GRM6GRM5CISD2KDM4EPKM | |
| SCHEMBL12297930 | 0.78 | ALDH1A1 (0.67) | GRM6GRM5CISD2PKMALDH1A1 | |
| SCHEMBL25106698 | 0.76 | CISD2 (1.00) | CISD2ALDH1A1MAPT | |
| SCHEMBL1381277 | 0.75 | CHEK1 (0.56) | GRM6GRM5KDM4EPKMALDH1A1 | |
| SCHEMBL10489630 | 0.75 | GRM6 (0.71) | GRM6GRM5CISD2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849738-B2 | Processes for the production of thienopyrimidine derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20030055269-A1 | Processes for the production of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1266898-A1 | PROCESSES FOR THE PRODUCTION OF THIENOPYRIMIDINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055269-A1 | Processes for the production of thienopyrimidine derivatives | GNRHR, NR5A1, DHODH | GRM6 136/4885GRM5 313/4885CISD2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.